VTVT vTv Therapeutics Inc.

NASDAQ
$30.12

vTv Therapeutics Inc. (VTVT) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $1.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.5% since its last earnings release on August 6, 2026.

vTv Therapeutics Missed Consensus Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($1.07)
Rev est $1M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $33.49

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.

Sector

Healthcare

Industry

Biotechnology